Opaleye Management Inc. Sells 47,993 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) major shareholder Opaleye Management Inc. sold 47,993 shares of Protara Therapeutics stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $2.40, for a total value of $115,183.20. Following the completion of the sale, the insider now owns 60,000 shares in the company, valued at $144,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Tuesday, July 9th, Opaleye Management Inc. sold 8,497 shares of Protara Therapeutics stock. The shares were sold at an average price of $2.21, for a total value of $18,778.37.
• On Monday, July 1st, Opaleye Management Inc. sold 8,288 shares of Protara Therapeutics stock. The stock was sold at an average price of $2.12, for a total transaction of $17,570.56.
• On Thursday, June 27th, Opaleye Management Inc. sold 46,574 shares of Protara Therapeutics stock. The stock was sold at an average price of $2.26, for a total transaction of $105,257.24.
• On Tuesday, June 25th, Opaleye Management Inc. sold 12,725 shares of Protara Therapeutics stock. The shares were sold at an average price of $2.26, for a total transaction of $28,758.50.
• On Thursday, May 30th, Opaleye Management Inc. sold 9,230 shares of Protara Therapeutics stock. The stock was sold at an average price of $2.94, for a total value of $27,136.20.
• On Tuesday, May 21st, Opaleye Management Inc. sold 33,000 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.06, for a total value of $100,980.00.
• On Friday, May 17th, Opaleye Management Inc. sold 70,885 shares of Protara Therapeutics stock. The stock was sold at an average price of $3.25, for a total value of $230,376.25.
• On Thursday, May 9th, Opaleye Management Inc. sold 30,600 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.09, for a total value of $94,554.00.

Protara Therapeutics Stock Up 0.9 %

Shares of NASDAQ:TARA opened at $2.36 on Friday. The company has a market capitalization of $48.59 million, a P/E ratio of -0.63 and a beta of 1.85. Protara Therapeutics, Inc. has a 52-week low of $1.04 and a 52-week high of $5.24. The stock’s fifty day simple moving average is $2.63 and its 200-day simple moving average is $2.97.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Thursday, May 2nd. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.02. On average, sell-side analysts anticipate that Protara Therapeutics, Inc. will post -3.56 earnings per share for the current year.

Institutional Trading of Protara Therapeutics

An institutional investor recently bought a new position in Protara Therapeutics stock. Oppenheimer & Co. Inc. purchased a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned 0.09% of Protara Therapeutics as of its most recent SEC filing. 38.13% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TARA shares. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday, May 6th. Oppenheimer raised their price objective on shares of Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Monday, April 22nd.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.